Max M. Nowicki

Max Nowicki is currently the Vice President of Acquisitions at Frazier Healthcare Partners, a prominent life sciences investment firm headquartered in Seattle, Washington. Before joining Frazier in 2019, he founded and managed King Tide Capital Management, an investment fund focused exclusively on public biotechnology equities. His earlier professional career includes serving as a senior business analyst at the synthetic biology company Zymergen and working as a healthcare mergers and acquisitions investment banking analyst at Evercore Partners. Nowicki earned a Doctor of Medicine from Weill Cornell Medical College and a Bachelor of Arts in physics and biochemistry from Bowdoin College. He has held board representative roles for multiple portfolio companies, including Alpine Immune Sciences, AnaptysBio, and Phathom Pharmaceuticals, while actively focusing on identifying public and private investment opportunities across the biotechnology and life sciences therapeutics sectors.